Meta-analysis of clinical metabolic profiling studies in cancer

challenges and opportunities

Jermaine Goveia, Andreas Pircher, Lena Christin Conradi, Joanna Kalucka, Vincenzo Lagani, Mieke Dewerchin, Guy Eelen, Ralph J. DeBerardinis, Ian D. Wilson, Peter Carmeliet

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Cancer cell metabolism has received increasing attention. Despite a boost in the application of clinical metabolic profiling (CMP) in cancer patients, a meta-analysis has not been performed. The primary goal of this study was to assess whether public accessibility of metabolomics data and identification and reporting of metabolites were sufficient to assess which metabolites were consistently altered in cancer patients. We therefore retrospectively curated data from CMP studies in cancer patients published during 5 recent years and used an established vote-counting method to perform a semiquantitative meta-analysis of metabolites in tumor tissue and blood. This analysis confirmed well-known increases in glycolytic metabolites, but also unveiled unprecedented changes in other metabolites such as ketone bodies and amino acids (histidine, tryptophan). However, this study also highlighted that insufficient public accessibility of metabolomics data, and inadequate metabolite identification and reporting hamper the discovery potential of meta-analyses of CMP studies, calling for improved standardization of metabolomics studies.

Original languageEnglish (US)
Pages (from-to)1134-1142
Number of pages9
JournalEMBO Molecular Medicine
Volume8
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Meta-Analysis
Metabolomics
Neoplasms
Ketone Bodies
Histidine
Tryptophan
Research Design
Amino Acids

Keywords

  • cancer
  • meta-analysis
  • metabolic profiling
  • metabolomics

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Goveia, J., Pircher, A., Conradi, L. C., Kalucka, J., Lagani, V., Dewerchin, M., ... Carmeliet, P. (2016). Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. EMBO Molecular Medicine, 8(10), 1134-1142. https://doi.org/10.15252/emmm.201606798

Meta-analysis of clinical metabolic profiling studies in cancer : challenges and opportunities. / Goveia, Jermaine; Pircher, Andreas; Conradi, Lena Christin; Kalucka, Joanna; Lagani, Vincenzo; Dewerchin, Mieke; Eelen, Guy; DeBerardinis, Ralph J.; Wilson, Ian D.; Carmeliet, Peter.

In: EMBO Molecular Medicine, Vol. 8, No. 10, 01.10.2016, p. 1134-1142.

Research output: Contribution to journalArticle

Goveia, J, Pircher, A, Conradi, LC, Kalucka, J, Lagani, V, Dewerchin, M, Eelen, G, DeBerardinis, RJ, Wilson, ID & Carmeliet, P 2016, 'Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities', EMBO Molecular Medicine, vol. 8, no. 10, pp. 1134-1142. https://doi.org/10.15252/emmm.201606798
Goveia J, Pircher A, Conradi LC, Kalucka J, Lagani V, Dewerchin M et al. Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. EMBO Molecular Medicine. 2016 Oct 1;8(10):1134-1142. https://doi.org/10.15252/emmm.201606798
Goveia, Jermaine ; Pircher, Andreas ; Conradi, Lena Christin ; Kalucka, Joanna ; Lagani, Vincenzo ; Dewerchin, Mieke ; Eelen, Guy ; DeBerardinis, Ralph J. ; Wilson, Ian D. ; Carmeliet, Peter. / Meta-analysis of clinical metabolic profiling studies in cancer : challenges and opportunities. In: EMBO Molecular Medicine. 2016 ; Vol. 8, No. 10. pp. 1134-1142.
@article{e05110bd235a43658baf2e9122f0a280,
title = "Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities",
abstract = "Cancer cell metabolism has received increasing attention. Despite a boost in the application of clinical metabolic profiling (CMP) in cancer patients, a meta-analysis has not been performed. The primary goal of this study was to assess whether public accessibility of metabolomics data and identification and reporting of metabolites were sufficient to assess which metabolites were consistently altered in cancer patients. We therefore retrospectively curated data from CMP studies in cancer patients published during 5 recent years and used an established vote-counting method to perform a semiquantitative meta-analysis of metabolites in tumor tissue and blood. This analysis confirmed well-known increases in glycolytic metabolites, but also unveiled unprecedented changes in other metabolites such as ketone bodies and amino acids (histidine, tryptophan). However, this study also highlighted that insufficient public accessibility of metabolomics data, and inadequate metabolite identification and reporting hamper the discovery potential of meta-analyses of CMP studies, calling for improved standardization of metabolomics studies.",
keywords = "cancer, meta-analysis, metabolic profiling, metabolomics",
author = "Jermaine Goveia and Andreas Pircher and Conradi, {Lena Christin} and Joanna Kalucka and Vincenzo Lagani and Mieke Dewerchin and Guy Eelen and DeBerardinis, {Ralph J.} and Wilson, {Ian D.} and Peter Carmeliet",
year = "2016",
month = "10",
day = "1",
doi = "10.15252/emmm.201606798",
language = "English (US)",
volume = "8",
pages = "1134--1142",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Meta-analysis of clinical metabolic profiling studies in cancer

T2 - challenges and opportunities

AU - Goveia, Jermaine

AU - Pircher, Andreas

AU - Conradi, Lena Christin

AU - Kalucka, Joanna

AU - Lagani, Vincenzo

AU - Dewerchin, Mieke

AU - Eelen, Guy

AU - DeBerardinis, Ralph J.

AU - Wilson, Ian D.

AU - Carmeliet, Peter

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Cancer cell metabolism has received increasing attention. Despite a boost in the application of clinical metabolic profiling (CMP) in cancer patients, a meta-analysis has not been performed. The primary goal of this study was to assess whether public accessibility of metabolomics data and identification and reporting of metabolites were sufficient to assess which metabolites were consistently altered in cancer patients. We therefore retrospectively curated data from CMP studies in cancer patients published during 5 recent years and used an established vote-counting method to perform a semiquantitative meta-analysis of metabolites in tumor tissue and blood. This analysis confirmed well-known increases in glycolytic metabolites, but also unveiled unprecedented changes in other metabolites such as ketone bodies and amino acids (histidine, tryptophan). However, this study also highlighted that insufficient public accessibility of metabolomics data, and inadequate metabolite identification and reporting hamper the discovery potential of meta-analyses of CMP studies, calling for improved standardization of metabolomics studies.

AB - Cancer cell metabolism has received increasing attention. Despite a boost in the application of clinical metabolic profiling (CMP) in cancer patients, a meta-analysis has not been performed. The primary goal of this study was to assess whether public accessibility of metabolomics data and identification and reporting of metabolites were sufficient to assess which metabolites were consistently altered in cancer patients. We therefore retrospectively curated data from CMP studies in cancer patients published during 5 recent years and used an established vote-counting method to perform a semiquantitative meta-analysis of metabolites in tumor tissue and blood. This analysis confirmed well-known increases in glycolytic metabolites, but also unveiled unprecedented changes in other metabolites such as ketone bodies and amino acids (histidine, tryptophan). However, this study also highlighted that insufficient public accessibility of metabolomics data, and inadequate metabolite identification and reporting hamper the discovery potential of meta-analyses of CMP studies, calling for improved standardization of metabolomics studies.

KW - cancer

KW - meta-analysis

KW - metabolic profiling

KW - metabolomics

UR - http://www.scopus.com/inward/record.url?scp=84989959246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989959246&partnerID=8YFLogxK

U2 - 10.15252/emmm.201606798

DO - 10.15252/emmm.201606798

M3 - Article

VL - 8

SP - 1134

EP - 1142

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 10

ER -